Medtronic CEO Omar Ishrak marked his first year on the job much the way he marked his first day – with a Tweet.
Ishrak, who is a regular poster on the social media site, reflected on the past year he spent jet-setting around the globe and learning the ropes at the helm of the world’s largest pure-play device maker.
"My first year at Medtronic," Ishrak wrote today. "Have traveled around the globe to Brazil, Italy, China, India & more. Learning a ton and having fun."
Ishrak’s celebrated his official 1-year anniversary last month, marking the date with a trio of Tweets:
Exactly 1 year before, Ishrak marked his 1st full day on the job with his 1st Tweet at the handle @MedtronicCEO:
However, the honeymoon period was short-lived. Just a few days into his tenure as CEO Ishrak was confronted with a major crisis: The Spine Journal devoted its entire June issue to to exposing problems with growth proteins, including a repudiation of some of the research surrounding Medtronic’s Infuse.
Read MassDevice.com’s exclusive interview with MDT CEO Omar Ishrak
Ishrak issued his 1st public statement as Medtronic CEO in response to the kerfuffle over the Infuse bone growth trials, defending the company’s data while maintaining the company’s commitment to eliminating conflicts of interest.
Prior to his ascension to the helm at Medtronic, Ishrak, a 16-year veteran of GE’s (NYSE:GE) $12 billion health care business, was also a senior VP and a member of the conglomerate’s executive council.
Before signing on with GE Healthcare in 1995, Ishrak put in more than 13 years in senior technology development and business management roles at Philips Ultrasound, Diasonics Inc. and Elbit Ultrasound Group.
